Economic evaluation of the clinical management of lung cancer in France

Vergnenègre, A.; Molinier, Laurent; Combescure, C.; Jp, Daurès; Schuller-Lebeau, M.P; Chouaïd, C.

doi:10.1016/s0959-8049(01)81344-7

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 To quantify the economic burden of cancer, both direct and indirect costs need to be considered. [3][4][5][6] Direct costs include all those costs associated with the diagnosis and further treatment of patients, including hospitalizations, pharmacotherapies, and surgical procedures. Indirect costs are mostly a result of loss of productivity due to premature cancer-related disability and death.…”

Section: Introductionmentioning

confidence: 99%

“…A third category, rarely taken into account, includes all intangible costs linked to the loss of well-being of the patient and his close family (psychological distress, pain, and suffering). 6 A population-based cost analysis estimated that the total economic cost of lung cancer across the European Union for 2009 was €18.8 million, accounting for 15% of overall cancer costs and thus the highest economic burden among the 4 types of cancers studied (colorectal, breast, lung, and prostate cancers). 3 Previous studies have examined the economic burden of lung cancer on a national level in various settings, [7][8][9][10][11][12][13][14][15] with the first and most ambitious model-based attempt made in Canada.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

End-of-Life Health-Care Cost of Patients With Lung Cancer: A Retrospective Study

Souliotis

Kani

Marioli

et al. 2019

Health Services Research and Managerial Epidemiology

View full text Add to dashboard Cite

Introduction: Lung cancer exerts a significant societal and health-care–related economic burden and chemotherapy drugs constitute a major factor of total direct cost. The aim of the present study was to assess the direct health-care cost of lung cancer in Greece by conducting a retrospective analysis on the last 6 months of life. Methods: The present study was based on both the medical data and costs of treatment of deceased adult patients who suffered from terminal stage IIIB/IV lung cancer (non-small cell lung cancer and small cell lung cancer) during the last 6 months of their life. The study’s protocol was approved by the Hospital’s Research Ethics Committee. Costs included outpatient (outpatient services) and inpatient (inpatient services) costs. Descriptive statistics were mainly used for statistical analysis. Results: The files of 144 patients were analyzed. The total cost of health-care services for the study population during the last 6 months of life was attributed by 57% to inpatient services, whereas chemotherapy costs (74%) comprised the largest proportion of the total inpatient cost. The highest expenditure for outpatient services was attributed to concomitant medication (59%), followed by the cost of tests (21%) and radiotherapy (20%). Conclusions: The results of our study indicate that both inpatient and outpatient costs were substantial. The main inpatient and outpatient cost drivers were chemotherapy and concomitant medication, respectively. A more comprehensive nationwide study would be useful to validate our results and to include also indirect costs of cancer care in Greece.

show abstract